ISSN: 2167-7719

Air & Water Borne Diseases
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • Air Water Borne Dis 2023, Vol 12(1): 168
  • DOI: 10.4172/2167-7719.1000168

Molecular Strategies of Ebola Virus for inventing the Ground Braking Drugs

Eric Ground*
Department of Immunology, Newcastle University, United Kingdom
*Corresponding Author : Eric Ground, Department of Immunology, Newcastle University, United Kingdom, Email: eric32ground@yahoo.com

Received Date: Feb 01, 2023 / Accepted Date: Feb 28, 2023 / Published Date: Feb 28, 2023

Abstract

The Ebola Virus (EBOV) is responsible for the severe and frequently fatal disease known as Ebola Virus Disease (EVD). EVD outbreaks typically begin with a single case of possible zoonotic transmission, which is followed by human-to-human transmission through direct contact or contact with contaminated fomites or bodily fluids. The case fatality rate of EVD is high; it has a fever, symptoms in the Gastrointestinal Tract, and the syndrome of Multiple Organ Dysfunction. Case definition and laboratory tests, typically Real Time Reverse Transcription PCR to detect viral RNA or Immunoassay Based Rapid Diagnostic Tests to detect EBOV antigens, are required for diagnosis. An EBOV-targeted vaccine was recently approved by regulatory agencies in the United States and Europe as a result of recent advancements in medical countermeasure research. The availability of these vaccines are most of the cases impossible specially the arena of developing countries due to their higher cost affectivity. Two monoclonal antibody products that target the EBOV membrane glycoprotein were found to improve survival rates in a randomized clinical trial of investigational therapies for EVD. New strategies for infection prevention and optimization of clinical management, acute illness outcomes, and patient attendance have been developed as a result of new observations made during the unprecedented Western African EVD outbreak (the largest in history) that occurred from 2013 to 2016 and the ongoing EVD outbreak in the Democratic Republic of the Congo. The consequences regarding vaccine technology and its availability, creates a turning of treatment methodologies to invent groundbreaking drugs against this zoonotic virus.

Citation: Ground E (2023) Molecular Strategies of Ebola Virus for inventing the Ground Braking Drugs. Air Water Borne Dis 12: 168. Doi: 10.4172/2167-7719.1000168

Copyright: © 2023 Ground E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top